<DOC>
	<DOC>NCT02679170</DOC>
	<brief_summary>Prospective Observational Study To Identify Patients With Advanced/metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management under clinical practice (IDEALK)</brief_summary>
	<brief_title>Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management (IDEALK)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Patients with Advanced or metastatic nonsmall cell lung cancer Patients who will be screened for anaplastic lymphoma kinase (ALK) rearrangement Age &gt; 18 years For the patients that will be recruited prospectively: Patients must have a signed informed consent document. For the treatment substudy, patients must also meet the following criteria Confirmed anaplastic lymphoma kinase (ALK)positive tumour Patients treated with crizotinib under routine clinical practice Patients with a minimum data registered at the medical history Any patient who does not meet any of the inclusion criteria defined in the previous section, depending on the substudy for which they are included.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ALK+</keyword>
</DOC>